G medical innovations holdings ltd. (nasdaq: gmvd) announces receipt of notice of deficiency with nasdaq continued listing requirements

Irvine, california, nov. 22, 2022 (globe newswire) -- g medical innovations holdings ltd. (nasdaq: gmvd) (the “company”), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, has received today a written notice (the “notice”) from nasdaq stock market llc, indicating that the company is no longer in compliance with the minimum shareholders' equity requirement for continued listing on the nasdaq capital market. nasdaq rule 5550(b)(1) requires listed companies to maintain shareholders' equity of at least $2,500,000. further, the company did not meet the alternative compliance standards relating to the market value of listed securities or net income from continuing operations, as set forth in nasdaq rule 5550(b)(1). in accordance with nasdaq rule 5810(c)(2)(a), the company has 45 calendar days, or until january 6, 2023, to submit a plan to regain compliance. if the plan is accepted, nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance. the notice has no immediate effect on the company's nasdaq listing or the trading of its ordinary shares on the nasdaq capital market under the symbol “gmvd”.
GMVD Ratings Summary
GMVD Quant Ranking